have increased with the implementation of donor milk feeding protocols as a supplement to mother's own milk (MOM) throughout the US. To date, no study has evaluated the risk of NEC in ELBW infants on bovine milk-based diets compared to exclusive human milk-based diets (HMBD). STUDY DESIGN: This was a single site retrospective (2006)(2007)(2008)(2009)(2010)(2011)(2012) cohort study of ELBW infants (birth weight <1000 g). Exclusion criteria included major congenital anomalies, death within 12 hours of admission, or outborns admitted after 1 week of age. Of the 576 infants meeting inclusion criteria, 238 (41.3%) received a bovine milk-based diet (BOV, a diet including formula and/or bovine milkbased fortification), and 338 infants (58.7%) received exclusive HMBD (no bovine products). Statistical methodology included Student's t-test, Fisher's exact test, and multivariate logistic regression. RESULTS: ELBW infants in the HMBD cohort had significantly lower odds of NEC (OR ¼0.39, 95% CI: 0.22-0.68, p<0.001), but not in mortality rates (OR ¼ 0.75, 95% CI: 0.50-1.12, p¼0.181). Characteristics between the two cohorts are seen in Table 1 . The mean length of stay was not different between the groups (92.3 AE 58.6 vs 94.5 AE 71.4 days, p¼0.674). After controlling for use of antenatal corticosteroids, indomethacin or ibuprofen for treatment of a PDA, and diagnosis with PDA or culture-positive sepsis, neonates in the HMBD cohort continued to have significantly lower odds of NEC (adjusted OR ¼ 0.42, 95% CI: 0.23-0.76, p¼0.005) (Figure 1) . CONCLUSION: We have demonstrated for the first time that among neonates at greatest risk for NEC (ELBW), we observed a significant reduction in NEC rates with the introduction of exclusive HMBD including expressed MOM, donor breast milk, and donor breast milk fortification products. These findings are the first to demonstrate that there is a nearly 60% reduction in the odds of NEC among <1000 gram neonates by limiting feeds to only human milk-based.
938 Maternal IgA targets commensal microbiota in breast milk and the maternal and infant gut microbiomes OBJECTIVE: Breast milk harbors high levels of IgA and a unique microbiome that is thought to contribute to the colonization of the infant gut microbiome. We sought to evaluate the relationship between microbes and maternal IgA in the maternal gut, breast milk, and infant gut of mother-infant dyads. We hypothesize that IgA targets commensal microbes in mothers and infants, and that bacterial strains are vertically transmitted from mother to infant contributing to the establishment of the infant microbiome. STUDY DESIGN: Breast milk (n ¼ 29), maternal stool (n ¼ 34), and neonatal and infant stool (n ¼ 28) samples were collected from healthy breastfeeding mother-infant dyads directly after delivery (n ¼ 8 dyads) and 4-6 weeks postpartum (n ¼ 20 dyads). For an additional 5 dyads, maternal stool samples were collected at 35-37 weeks gestation. The microbiome was profiled using Whole Genome Shotgun (WGS) sequencing, and a subset of samples were stained with PE-conjugated anti-IgA antibodies and subjected to fluorescence-activated cell sorting to isolate and identify IgA-bound (IgA+) bacteria and unbound (IgA-) bacteria. RESULTS: The milk microbiome is distinct from the maternal and infant gut microbiota, (A, p ¼ 0.001), and both the milk microbiome (B, p ¼ 0.032) and infant gut microbiome (C, p ¼ 0.001) mature from delivery to 4-6 weeks postpartum. WGS profile of IgAbound bacteria reveals multiple commensal species including Bifidobacterium, Lactobacillus, and Streptococcus spp. are targeted by IgA in all body sites (C). Average abundance of Bifidobacterium spp. in meconium samples reveals they are present at low abundance in meconium potentially due to in utero transmission, and bloom postpartum with breastfeeding. Phylogenetic analysis of all B. longum strains reveals identical strains are found in both maternal stool and infant stool from the same dyad, suggesting vertical transmission of B. longum from mother to infant. CONCLUSION: Maternal IgA targets numerous commensal bacteria in the maternal gut, breast milk, and infant gut. The infant gut contains many species identified in breast milk, and strain-level tracking of bacteria from the same mother-infant pair demonstrates identical strains are shared by mother and infant. Together this suggests that maternal IgA may play a role beyond protecting infants from infections, and that bacteria may be vertically transferred from mother to infant. OBJECTIVE: HMOs are unique, abundant oligosaccharides found in human milk that are indigestible by the infant yet serve to favor proliferation of beneficial microbes in the infant gut. To date, most studies of HMOs have evaluated interaction with gut bacteria such as Bifidobacterium and Lactobacillus spp., yet the interaction with abundant milk microbes has remained largely unexplored. In the present study, we sought to evaluate if HMOs are utilized by Streptococcus and Staphylococcus spp., the two dominant genera of microbes present in human milk. STUDY DESIGN: Streptococcus spp. (S. mitis, S. oralis, S. parasanguinis, S. cristatus, and S. thermophilus) and Staphylococcus spp. (S. epidermidis and S. aureus) found to be present in the human milk microbiome were evaluated for growth on 2'-fucosyllactose (2'FL), the most abundant HMO in human milk for the majority of women.
S. mitis was additionally tested for growth with lacto-N-fucopentaose (LNFP) I, another abundant fucosylated HMO. Pure cultures were grown on thioglycollate medium with and without supplementation with individual HMOs (2'FL or LNFP I) at a concentration of 3 mg/ mL. Growth was monitored for 24 hours and carrying capacity was determined from corrected OD600 measurements. RESULTS: Supplementation of media with 2'FL conferred a growth advantage to S. mitis and S. oralis, two species abundant in human milk that possess fucosidase, a gene than enables digestion of fucose moieties (p < 0.001), and LNFP I additionally confers a growth advantage to S. mitis (p ¼ 0.0099). 2'FL does not confer a growth advantage to S. epidermidis nor S. aureus, the latter of which is a common causative agent of mastitis. CONCLUSION: Fucosylated HMOs found to be abundant in human milk favor proliferation of S. mitis and S. oralis, two common, abundant commensal milk microbes. Notably, fucosylated HMOs do not confer a growth advantage to the two most common Staphylococcus spp. present in human milk. We speculate that HMO-driven proliferation of Streptococcus commensals serves to maintain bacterial diversity in the milk microbiome, allowing commensals to outcompete potential pathobionts such as S. aureus. In this way, HMOs may serve to prevent the bacterial dysbiosis that leads to the development of mastitis.
